Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

BioFocus Launches Academic Engagement Initiative

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Aim of the initiative is to identify the best new therapeutic strategy ideas from academic groups.

BioFocus has announced that it has launched its Academic Engagement initiative (AEi). Based on years of experience working with academic and non-profit institutions, the primary aim of the initiative is to identify the best new therapeutic strategy ideas from academic groups, and to provide an effective and user-friendly mechanism to progress these ideas towards high quality chemical matter.

As part of the interaction model, BioFocus will contribute to grant writing and will provide ideas on funding mechanisms, but will not seek to retain any IP related to the projects; this will remain with the idea-originating institution.

“BioFocus has been assisting researchers to translate their discoveries into small molecule space for many years and will continue to enable these exciting early-stage projects,” said Professor Julie Frearson, BioFocus’ Senior Director Scientific Alliances and Translational Programs.

Professor Frearson continued, “BioFocus is also well positioned to take key projects to preclinical proof of concept and beyond towards candidate nomination.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Under the terms of the agreement, BioFocus will apply its drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio.
Thursday, November 21, 2013
BioFocus Signs Agreement with Aviva Investors
Pre-let agreement for construction of new laboratory and HQ building at Chesterford Research Park.
Thursday, September 05, 2013
BioFocus Achieves Milestone in its Drug Discovery Collaboration with UCB
Discovery milestone triggers payment from UCB and demonstrates BioFocus’ ability to support its clients.
Tuesday, December 04, 2012
BioFocus and Argenta Announce Drug Discovery Collaboration
Collaboration with AstraZeneca in respiratory and inflammatory disease.
Thursday, March 15, 2012
Argenta and BioFocus Announce Two-Year Extension Of Drug Discovery Collaboration with Genentech
Total potential value of the contract extension is up to £21.5 million (€23.4 million).
Monday, August 22, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
IMD will make natural product screening libraries available and provide follow-on services to BioFocus.
Wednesday, July 20, 2011
BioFocus Extends Collaboration with Usher III Initiative
BioFocus will further advance the project with the objective of delivering a pre-clinical candidate.
Wednesday, June 22, 2011
Ono and BioFocus Sign Target Discovery Agreement in the Field of Autoimmune Disease
Under the agreement, BioFocus will receive research funding and success payments based on the progress of the collaboration.
Wednesday, January 12, 2011
BioFocus Extends Collaboration with Amgen into 2012
BioFocus has announced that it has extended its contract with Amgen for 2011 and 2012, with an expansion to include target discovery and validation services.
Friday, December 17, 2010
BioFocus and the National Cancer Institute Sign Compound Management Agreement
BioFocus will provide compound management services to NCI for a base period of three years for a total of up to $5 million.
Wednesday, October 13, 2010
BioFocus and Usher III Initiative, Inc. Announce Collaboration
Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences.
Thursday, September 09, 2010
BioFocus Renews French Research Tax Credit Accreditation
The accreditation allows eligible French companies to benefit from significant tax relief on research carried out by BioFocus on their behalf until 2013.
Wednesday, June 09, 2010
BioFocus to Host Free Webinar on “Unleashing the Power of Computational Chemistry in Hit Finding Campaigns”
Attendees will learn how computational chemistry tools enable cost- and time-efficient HTS campaigns.
Friday, May 07, 2010
BioFocus Launches Four Compound Libraries Targeting Kinases and Protein-protein Interactions
BioFocus, a leading provider of gene-to-clinical candidate drug discovery services, has announced the launch of four biologically targeted libraries. These new libraries contain novel, drug-like compounds that specifically target kinases and protein-protein interactions.
Tuesday, May 04, 2010
BioFocus Announces its Free Educational Webinars for Drug Discovery Researchers - “Focus on Permeability”
The webinar will guide scientists in the implementation of ADME assays in early drug discovery, and on how best to use the data obtained.
Tuesday, April 27, 2010
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos